

FDA ALIGNMENT ON REGISTRATIONAL TRIAL DESIGN IN BLINDING EYE DISEASE

- **PYC is developing a drug candidate (known as VP-001) to treat a blinding eye disease of childhood called Retinitis Pigmentosa type 11 (RP11)**
- **RP11 patients enrolled in PYC's ongoing Phase 1/2 studies have demonstrated improvements in both visual acuity and retinal sensitivity following treatment with VP-001¹**
- **PYC is planning on progressing into a registrational Phase 2/3 study in RP11 and recently engaged the FDA on the path to a New Drug Application (NDA) for VP-001²**
- **Key outcomes of the meeting included confirmation by the FDA that:**
 - **PYC's proposal to include a sham control arm within the registrational trial is acceptable;**
 - **PYC's proposed inclusion and exclusion criteria for the study are acceptable;**
 - **Either endpoint PYC is tracking in the ongoing Phase 1/2 studies can be nominated as the primary endpoint in the registrational study³; and**
 - **24-months or more of data from the registrational study will be required to support the NDA⁴**
- **PYC will use this guidance to finalise its proposed registrational study design prior to seeking endorsement of the protocol by the FDA in H2 2025 and initiating the trial**

PERTH, Australia and SAN FRANCISCO, California – 23 June 2025

PYC Therapeutics (ASX:PYC) (**PYC** or **the Company**) is a clinical-stage biotechnology company creating first in class precision therapies for patients with genetic diseases and

¹ Low Luminance Visual Acuity (LLVA) and Microperimetry – see ASX announcement of 28 April 2025

² Subject to the risks and uncertainties outlined in the Company's ASX disclosures of 17 February 2025

³ The two endpoints are LLVA and Microperimetry

⁴ The minimum data requirement excludes a potential application for accelerated approval by PYC

no treatment options available. One of the Company's assets is an investigational drug candidate (known as VP-001) that addresses the underlying cause of a blinding eye disease of childhood called Retinitis Pigmentosa type 11 (RP11).

PYC is currently progressing VP-001 through combined Phase 1/2 studies in patients with RP11. Improvements in both visual acuity (as assessed by Low Luminance Visual Acuity (LLVA)) and retinal sensitivity (as assessed by microperimetry) have been observed in patients who have received VP-001¹.

PYC is planning on progressing VP-001 into a registrational study in RP11 and recently held a Type B meeting with the US Food and Drug Administration (FDA) to discuss the requirements to support a New Drug Application (NDA) for VP-001. The FDA confirmed in this meeting that either LLVA or microperimetry can be used as the sole primary endpoint in a registrational trial. The FDA also set out an expectation that the NDA contains a minimum of 24-months of data in support of VP-001⁴.

In addition, the FDA also confirmed that PYC's proposed inclusion of a sham control arm within the study (for comparison with the interventional arm) and the proposed inclusion and exclusion criteria for the registrational trial are acceptable to the regulator.

PYC will use the guidance obtained in this meeting to finalise the registrational study design before seeking endorsement of the proposal from the FDA through a type D meeting expected to occur in H2 2025. Once final alignment with the FDA has been achieved, PYC will initiate the registrational trial for VP-001².

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – **the indications with the highest likelihood of success in clinical development**⁵.

For more information, visit pyctx.com, or follow us on LinkedIn and Twitter.

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

⁵ Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank <https://doi.org/10.1101/2020.11.02.20222232>

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited

CONTACTS:

INVESTORS and MEDIA

investor@pyctx.com